2016
Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.
Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea. Journal Of Clinical Sleep Medicine 2016, 12: 9-17. PMID: 26194728, PMCID: PMC4702197, DOI: 10.5664/jcsm.5382.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaOrexin receptor antagonistMean AHIRespiratory effectsSleep apneaMultiple dosesReceptor antagonistIntra-individual variabilityModerate obstructive sleep apneaEffects of suvorexantLowest effective doseSleep laboratory studiesTotal sleep timeMean SpO2Single doseRespiratory functionOxygen saturationPulse oximetryPlaceboPatientsSleep timeAHIDay 4Mean increaseSuvorexant
2015
Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease
Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rowe J, Lines C, Wagner JA, Troyer MD. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respiratory Medicine 2015, 109: 416-426. PMID: 25661282, DOI: 10.1016/j.rmed.2014.12.010.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAzepinesCross-Over StudiesDouble-Blind MethodFemaleHumansMaleMiddle AgedOrexin Receptor AntagonistsPulmonary Disease, Chronic ObstructiveRespirationSeverity of Illness IndexSleepSleep Aids, PharmaceuticalSpirometryTreatment OutcomeTriazolesUnited StatesConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseSleep breathing disordersOrexin receptor antagonistPulmonary diseaseBreathing disordersReceptor antagonistModerate chronic obstructive pulmonary diseaseDay 4Effects of suvorexantModerate airflow limitationRespiratory depressant effectsApnea-hypopnea indexMaximum daily doseClinical research unitTotal sleep timeTreatment of insomniaMean AHICOPD patientsAirflow limitationHypopnea indexDaily doseMean SpO2Spirometry criteriaHypnotic medications
2012
Respiratory Event Detection by a Positive Airway Pressure Device
Berry RB, Kushida CA, Kryger MH, Soto-Calderon H, Staley B, Kuna ST. Respiratory Event Detection by a Positive Airway Pressure Device. Sleep 2012, 35: 361-367. PMID: 22379242, PMCID: PMC3274337, DOI: 10.5665/sleep.1696.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaEvents/hrPositive airway pressure devicesApnea indexHypopnea indexPAP devicesRespiratory eventsSleep disorders centerPressure deviceBetter treatment efficacyRespiratory event detectionOxygen desaturationSleep apneaPAP treatmentBland-Altman analysisDisorders CenterPolysomnographyTreatment efficacyAHIInadequate treatmentManual scoringHypopnea detectionTrue negative eventsHrTreatment
2011
Positive Airway Pressure Initiation: A Randomized Controlled Trial to Assess the Impact of Therapy Mode and Titration Process on Efficacy, Adherence, and Outcomes
Kushida CA, Berry RB, Blau A, Crabtree T, Fietze I, Kryger MH, Kuna ST, Pegram GV, Penzel T. Positive Airway Pressure Initiation: A Randomized Controlled Trial to Assess the Impact of Therapy Mode and Titration Process on Efficacy, Adherence, and Outcomes. Sleep 2011, 34: 1083-1092. PMID: 21804670, PMCID: PMC3138163, DOI: 10.5665/sleep.1166.Peer-Reviewed Original ResearchConceptsContinuous positive airway pressurePositive airway pressureMinimum oxygen saturationAirway pressureFunctional outcomeOxygen saturationVeterans Affairs Medical CenterPositive pressure treatmentApnea-hypopnea indexObstructive sleep apneaSevere OSAMulticenter trialTreatment satisfactionControlled TrialsSleep apneaMajor efficacyStudy treatmentOutcome measuresMedical CenterSleep qualityTherapy modesMask comfortAdherenceEfficacyMonthsA Novel Nasal Expiratory Positive Airway Pressure (EPAP) Device for the Treatment of Obstructive Sleep Apnea: A Randomized Controlled Trial
Berry RB, Kryger MH, Massie CA. A Novel Nasal Expiratory Positive Airway Pressure (EPAP) Device for the Treatment of Obstructive Sleep Apnea: A Randomized Controlled Trial. Sleep 2011, 34: 479-485. PMID: 21461326, PMCID: PMC3065258, DOI: 10.1093/sleep/34.4.479.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaPositive airway pressure devicesSleep apneaSham deviceWeek 1Double-blind clinical trialSevere obstructive sleep apneaMonths of treatmentSleep disorders centerEpworth Sleepiness ScalePressure deviceSubjective daytime sleepinessNon-consecutive nightsControlled TrialsMonth 3Sham treatmentClinical trialsDaytime sleepinessITT groupDisorders CenterSleepiness ScaleAHI valuesApneaMedian percentageAHI
2008
The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease
Kryger M, Roth T, Wang-Weigand S, Zhang J. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep And Breathing 2008, 13: 79-84. PMID: 18584227, DOI: 10.1007/s11325-008-0196-4.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultComorbidityCross-Over StudiesDouble-Blind MethodFemaleHumansIndenesMaleOximetryPolysomnographyPulmonary Disease, Chronic ObstructiveReceptors, MelatoninSeverity of Illness IndexSleep Apnea SyndromesSleep Apnea, ObstructiveSleep Initiation and Maintenance DisordersSleep StagesYoung AdultConceptsSevere chronic obstructive pulmonary diseaseChronic obstructive pulmonary diseaseEffects of ramelteonObstructive pulmonary diseasePulmonary diseaseMean SaO2Respiratory depressant effectsApnea-hypopnea indexPoor sleep qualityTotal sleep timeMelatonin receptor agonistResultsNo significant differencesSignificant differencesAbnormal breathing eventsRamelteon 8Primary endpointAdverse eventsPersistent sleepCrossover studyDepressant effectPolysomnographic monitoringReceptor agonistRespiratory effortInsomnia treatmentSleep quality
2007
Effect of Ramelteon, a selective MT1/MT2-receptor agonist, on respiration during sleep in mild to moderate COPD
Kryger M, Wang-Weigand S, Zhang J, Roth T. Effect of Ramelteon, a selective MT1/MT2-receptor agonist, on respiration during sleep in mild to moderate COPD. Sleep And Breathing 2007, 12: 243-250. PMID: 18060441, DOI: 10.1007/s11325-007-0156-4.Peer-Reviewed Original ResearchConceptsModerate chronic obstructive pulmonary diseaseChronic obstructive pulmonary diseaseAbnormal breathing eventsSelective MT1/MT2 receptor agonistMT1/MT2 receptor agonistMean apnea-hypopnea indexBreathing eventsEffects of ramelteonMT2 receptor agonistSingle bedtime doseApnea-hypopnea indexObstructive pulmonary diseaseNumber of awakeningsTotal sleep timeMelatonin receptor agonistBedtime dosePlacebo groupAdverse eventsPulmonary diseaseCrossover studyPhysical examinationReceptor agonistSleep efficiencySleep durationSleep timeSafety of ramelteon in individuals with mild to moderate obstructive sleep apnea
Kryger M, Wang-Weigand S, Roth T. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep And Breathing 2007, 11: 159-164. PMID: 17294232, DOI: 10.1007/s11325-006-0096-4.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaNext-day residual effectsApnea-hypopnea indexSleep apneaPost-sleep questionnaireAdverse eventsSelective MT1/MT2 receptor agonistMT1/MT2 receptor agonistMT2 receptor agonistSafety of ramelteonUrinary tract infectionArterial oxygen saturationControl of breathingRespiratory inductance plethysmographyRamelteon groupPlacebo groupTract infectionsCrossover studyWashout periodDepressant effectSleep QuestionnaireHypopneic eventsRespiratory effortInsomnia treatmentOxygen saturation
1999
Upper Airway Resistance Syndrome: Effect of Nasal Dilation, Sleep Stage, and Sleep Position
Bahammam A, Tate R, Manfreda J, Kryger M. Upper Airway Resistance Syndrome: Effect of Nasal Dilation, Sleep Stage, and Sleep Position. Sleep 1999, 22: 592-598. PMID: 10450594, DOI: 10.1093/sleep/22.5.592.Peer-Reviewed Original ResearchConceptsUpper airway resistance syndromeStage 1 sleepSleep positionNasal dilationDesaturation timeSleep architectureExternal nasal dilationArousal indexCardiorespiratory parametersSleep stagesNREM sleepNasal cross-sectional areaExternal nasal dilatorSlow-wave sleepObstructive sleepAirway collapsibilityConsecutive patientsNasal dilatorNasal obstructionResistance syndromeSupine positionIntrapharyngeal pressureIndirect markerWave sleepCrossover design
1997
Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy
Broughton R, Fleming J, George C, Hill J, Kryger M, Moldofsky H, Montplaisir J, Morehouse R, Moscovitch A, Murphy W. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997, 49: 444-451. PMID: 9270575, DOI: 10.1212/wnl.49.2.444.Peer-Reviewed Original ResearchConceptsPlacebo-controlled crossover trialOnly significant adverse effectPlacebo-controlled trialExcessive daytime somnolenceMean sleep latencyPeriodic leg movementsEpworth Sleepiness ScaleDaytime sleep episodesInternational diagnostic criteriaSignificant adverse effectsHypertensive patientsMore nauseaBlood pressureDaily doseDaytime somnolenceExcessive daytimeSleep apneaCrossover trialSleep latencyModafinil 200Nocturnal sleepPatient's abilitySleepiness ScaleSleep initiationHeart rate
1996
L-DOPA/Carbidopa for Nocturnal Movement Disorders in Uremia
Walker S, Fine A, Kryger M. L-DOPA/Carbidopa for Nocturnal Movement Disorders in Uremia. Sleep 1996, 19: 214-218. PMID: 8723378, DOI: 10.1093/sleep/19.3.214.Peer-Reviewed Original ResearchConceptsL-dopa/carbidopaRestless legs syndromeSlow-wave sleepLeg movementsSleep timeTreatment of RLSMovement arousal indexNocturnal movement disordersSingle bedtime doseChronic hemodialysis patientsPeriodic limb movementsHours of sleepBedtime doseActive medicationHemodialysis patientsCrossover studyLegs syndromeUremic patientsArousal indexMovement disordersSleep disruptionFrequent dosingObjective improvementSleep disordersEffective treatment
1993
Effects of Zolpidem and Triazolam on Sleep and Respiration in Mild to Moderate Chronic Obstructive Pulmonary Disease
Steens R, Pouliot Z, Millar T, Kryger M, George C. Effects of Zolpidem and Triazolam on Sleep and Respiration in Mild to Moderate Chronic Obstructive Pulmonary Disease. Sleep 1993, 16: 318-326. PMID: 8341892, DOI: 10.1093/sleep/16.4.318.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseModerate chronic obstructive pulmonary diseaseObstructive pulmonary diseaseEffects of zolpidemPulmonary diseaseDrug conditionsNocturnal arterial oxygen desaturationArterial oxygen desaturationApnea-hypopnea indexGroup of patientsArterial oxygen saturationNumber of awakeningsTotal sleep timeHours of sleepSignificant differencesSubjective sleep variablesNew hypnotic agentOxygen desaturationCrossover studyHypnotic agentsSleep problemsSleep qualityOxygen saturationSleep efficiencyActive drug
1991
Sleep quality in children with asthma treated with theophylline or cromolyn sodium
Avital A, Steljes D, Pasterkamp H, Kryger M, Sanchez I, Chernick V. Sleep quality in children with asthma treated with theophylline or cromolyn sodium. The Journal Of Pediatrics 1991, 119: 979-984. PMID: 1960623, DOI: 10.1016/s0022-3476(05)83062-8.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAsthmaChildCromolyn SodiumDouble-Blind MethodFemaleHumansMaleSleepTheophyllineConceptsCromolyn sodiumTheophylline periodPlacebo-controlled trialArterial oxygen desaturationTheophylline blood levelsArterial oxygen saturationTotal sleep timeYears of ageOxygen desaturationPulmonary functionTheophylline treatmentBlood levelsChild's asthmaCentral originSleep latencyProtective effectSleep qualityOxygen saturationSleep efficiencySleep timeAsthmaMicrograms/SleepMovement timeTreatmentEffect of Theophylline on Lung Function Tests, Sleep Quality, and Nighttime SaO2 in Children with Cystic Fibrosis
Avital A, Sanchez I, Holbrow J, Kryger M, Chernick V. Effect of Theophylline on Lung Function Tests, Sleep Quality, and Nighttime SaO2 in Children with Cystic Fibrosis. American Journal Of Respiratory And Critical Care Medicine 1991, 144: 1245-1249. PMID: 1741534, DOI: 10.1164/ajrccm/144.6.1245.Peer-Reviewed Original ResearchMeSH KeywordsChildCystic FibrosisDouble-Blind MethodFemaleHeart RateHumansMaleMonitoring, PhysiologicOxygenRespiratory Function TestsSleepTheophyllineConceptsEffect of theophyllineCystic fibrosisMicrograms/Heart rateGroup 2Better baseline lung functionT blood levelsBaseline lung functionIncidence of apneaLung function testsSerum T levelsLower heart rateTotal wake timePulmonary functionLung functionSerum levelsFunction testsMean SaO2Blood levelsSleep qualitySleep efficiencyGroup 1Sleep laboratoryT levelsWake time
1989
The Effect of L-Tryptophan on Daytime Sleep Latency in Normals: Correlation with Blood Levels
George C, Millar T, Hanly P, Kryger M. The Effect of L-Tryptophan on Daytime Sleep Latency in Normals: Correlation with Blood Levels. Sleep 1989, 12: 345-353. PMID: 2669092, DOI: 10.1093/sleep/12.4.345.Peer-Reviewed Original ResearchConceptsSleep latencyBlood levelsRandom double-blind fashionRapid eye movement (REM) sleepDaytime sleep latencyL-tryptophan's effectsDouble-blind fashionEye movement sleepL-tryptophanSlow-wave sleepL-tryptophan levelsObjective sleepiness measuresKynurenic acidMovement sleepHealthy volunteersWave sleepDrug conditionsSeparate daysSleepSleepiness measuresPlaceboSignificant correlationEssential amino acidsDoseUrine
1983
The role of protriptyline in obstructive sleep apnea.
Brownell L, Perez-Padilla R, West P, Kryger M. The role of protriptyline in obstructive sleep apnea. Bulletin Européen De Physiopathologie Respiratoire 1983, 19: 621-4. PMID: 6360257.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaSleep apneaTreatment of mildLong-term treatmentTricyclic agentsObese patientsObstructive apneaClinical statusCrossover trialImproved oxygenationInvasive treatmentTerm treatmentPatientsApneaArousal frequencySomnolenceProtriptylineTreatmentTrialsOxygenationREMTherapyMildMonths
1982
Protriptyline in Obstructive Sleep Apnea — A Double-Blind Trial
Brownell L, West P, Sweatman P, Acres J, Kryger M. Protriptyline in Obstructive Sleep Apnea — A Double-Blind Trial. New England Journal Of Medicine 1982, 307: 1037-1042. PMID: 6750396, DOI: 10.1056/nejm198210213071701.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaSleep apneaTotal sleep timeApnea timeApnea durationBody weightSleep timeDouble-blind crossover studyDouble-blind trialMonths of treatmentWeeks of treatmentNocturnal oxygenationREM reductionDaytime somnolenceCrossover studyTricyclic antidepressantsApneaArousal frequencySimilar decreaseProtriptylineSimilar improvementsTreatmentOxygenationDurationSomnolence